CellaVision Yönetim

Yönetim kriter kontrolleri 2/4

CellaVision CEO'su Simon Ostergaard, Mar2021 tarihinde atandı, in görev süresi 3.67 yıldır. şirketin hisselerinin 0.021% doğrudan sahiptir ve bu hisselerin değeri € 92.49K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.8 yıl ve 3.8 yıldır.

Anahtar bilgiler

Simon Ostergaard

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	3.7yrs
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	3.8yrs
Yönetim Kurulu ortalama görev süresi	3.8yrs

Son yönetim güncellemeleri

Recent updates

CEO

Simon Ostergaard (53 yo)

3.7yrs

Görev süresi

Mr. Simon Ostergaard has been the Chief Executive Officer and President at CellaVision AB (publ) since March 21, 2021. He has broad experience is primarily in CellaVision's adjacent area of pathology and o...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christer Fahraeus	Founder & Director	no data	SEK 285.00k	6.83% € 30.1m
Simon Ostergaard	CEO & President	3.7yrs	Veri yok	0.021% € 92.5k
Magnus Blixt	Chief Financial Officer	11.5yrs	Veri yok	0.017% € 74.0k
Adele Horn	Corporate Communications & Investor Relations Manager	no data	Veri yok	Veri yok
Peter Wilson	Vice President of Global Marketing	no data	Veri yok	0.013% € 55.5k
Urban Strindlov	Vice President of Global Sales	2.8yrs	Veri yok	Veri yok
Nina Wallander	Vice President of Human Resources	3.8yrs	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

57.5yo

Ortalama Yaş

Deneyimli Yönetim: C26 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christer Fahraeus	Founder & Director	30.8yrs	SEK 285.00k	6.83% € 30.1m
Mikael Worning	Independent Chairman of the Board	4.8yrs	SEK 800.00k	0.0099% € 43.6k
Stefan Wolf	Independent Director	6.5yrs	SEK 260.00k	Veri yok
Ann-Charlotte Jarleryd	Independent Director	2.5yrs	SEK 360.00k	Veri yok
Kent Strahlen	Independent Employee Representative Director	2.8yrs	Veri yok	0.0042% € 18.5k
Louise Armstrong-Denby	Independent Director	1.5yrs	SEK 130.00k	Veri yok

3.8yrs

Ortalama Görev Süresi

58.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: C26 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).

CellaVision Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

CellaVision AB (publ), Annual General Meeting, May 06, 2025

Founder & Director recently sold €2.4m worth of stock

CellaVision AB (publ) Announces the Appointment of Emil Hjalmarsson as Chairman of the Nomination Committee

Founder & Director recently sold €1.1m worth of stock

CellaVision Announces Executive Changes

Sören Mellstig Not Stands for Re-election as Chairman of the Board of CellaVision AB

Recent updates

Investor sentiment deteriorates as stock falls 17%

CellaVision AB (publ), Annual General Meeting, May 06, 2025

Now 21% undervalued

Third quarter 2024 earnings released: EPS: kr1.30 (vs kr1.09 in 3Q 2023)

Founder & Director recently sold €2.4m worth of stock

Now 24% undervalued

Second quarter 2024 earnings released: EPS: kr1.62 (vs kr1.46 in 2Q 2023)

Now 24% undervalued

Now 21% undervalued

Investor sentiment improves as stock rises 17%

First quarter 2024 earnings released: EPS: kr1.26 (vs kr0.81 in 1Q 2023)

Full year 2023 earnings released: EPS: kr5.46 (vs kr4.96 in FY 2022)

Now 20% undervalued

Now 21% undervalued

Dividend of kr2.25 announced

Full year 2023 earnings released: EPS: kr5.46 (vs kr4.96 in FY 2022)

Investor sentiment improves as stock rises 32%

Now 25% undervalued

Now 22% undervalued after recent price drop

Investor sentiment improves as stock rises 18%

Third quarter 2023 earnings released: EPS: kr1.09 (vs kr0.43 in 3Q 2022)

CellaVision AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

CellaVision AB (publ) to Report Q3, 2023 Results on Oct 25, 2023

Now 20% undervalued after recent price drop

Second quarter 2023 earnings released: EPS: kr1.46 (vs kr1.56 in 2Q 2022)

CellaVision AB (publ) to Report Q2, 2023 Results on Jul 20, 2023

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 19%

Cellavision AB (Publ) Approves Dividend, Payable on May 12, 2023

Upcoming dividend of kr2.25 per share at 1.3% yield

Investor sentiment improves as stock rises 15%

Full year 2022 earnings released: EPS: kr4.96 (vs kr5.26 in FY 2021)

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

Full year 2022 earnings released: EPS: kr4.96 (vs kr5.26 in FY 2021)

Now 24% undervalued after recent price drop

Cellavision AB (Publ) Proposes Dividend for 2022

Now 22% undervalued after recent price drop

Investor sentiment improved over the past week

CellaVision AB (publ) Announces the Appointment of Emil Hjalmarsson as Chairman of the Nomination Committee

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings released: EPS: kr0.43 (vs kr1.09 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

CellaVision® Launches a Complete Workflow Solution for Low-Volume Hematology Laboratories

Second quarter 2022 earnings released: EPS: kr1.56 (vs kr1.30 in 2Q 2021)

Cellavision AB (Publ) Announces Dividend, Payable on 18 May 2022

First quarter 2022 earnings released: EPS: kr1.61 (vs kr1.19 in 1Q 2021)

Upcoming dividend of kr2.00 per share

Full year 2021 earnings released: EPS: kr5.26 (vs kr3.75 in FY 2020)

Investor sentiment improved over the past week

Cellavision AB (Publ) Proposes Dividend for 2021

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS kr1.09 (vs kr0.56 in 3Q 2020)

Founder & Director recently sold €1.1m worth of stock

Second quarter 2021 earnings released: EPS kr1.30 (vs kr1.14 in 2Q 2020)

Independent Chairman of the Board Sören Mellstig has left the company

CellaVision AB (publ) Approves Dividend, Payable on 6 May 2021

Upcoming dividend of kr0.75 per share

Full year 2020 earnings released: EPS kr3.75 (vs kr4.16 in FY 2019)

Revenue misses expectations

Full year 2020 earnings released: EPS kr3.75 (vs kr4.16 in FY 2019)

New 90-day high: €32.02

CellaVision Announces Executive Changes

New 90-day low: €27.24

Market pulls back on stock over the past week

Sören Mellstig Not Stands for Re-election as Chairman of the Board of CellaVision AB

New 90-day high: €33.86

New 90-day high - €30.56